Erratum to: Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments

Jennifer L. Pauley · John C. Panetta · Kristine R. Crews · Deqing Pei · Cheng Cheng · John McCormick · Scott C. Howard · John T. Sandlund · Sima Jeha · Raul Ribeiro · Jeffrey Rubnitz · Ching-Hon Pui · William E. Evans · Mary V. Relling

Published online: 29 October 2013
© Springer-Verlag Berlin Heidelberg 2013

Erratum to: Cancer Chemother Pharmacol (2013) 72:369–378
DOI 10.1007/s00280-013-2206-x

The author would like to correct the error in the publication of the original article. The corrected detail is given below for your reading.

The fourth sentence in the second paragraph of the Patients and methods section should read as:

If the patient had not received HDmtX as part of window therapy, then their first course of HDmtX in consolidation was a fixed dose of 2.5 g/m² (low-risk arm) or 5 g/m² (standard-/high-risk arm) infused over 24 h.

The online version of the original article can be found under doi:10.1007/s00280-013-2206-x.